Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug–Drug Interaction Concerns

2.50
Hdl Handle:
http://hdl.handle.net/10757/622329
Title:
Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug–Drug Interaction Concerns
Authors:
Braun, Hannan M.; Candelario, Jury; Hanlon, Courtney L.; Segura, Eddy R. ( 0000-0003-3580-7712 ) ; Clark, Jesse L.; Currier, Judith S.; Lake, Jordan E.
Citation:
Transgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug–Drug Interaction Concerns 2017, 4 (5):371 LGBT Health
Publisher:
Mary Ann Liebert Inc.
Journal:
LGBT Health
Issue Date:
Oct-2017
URI:
http://hdl.handle.net/10757/622329
DOI:
10.1089/lgbt.2017.0057
Additional Links:
http://online.liebertpub.com/doi/10.1089/lgbt.2017.0057
Abstract:
Purpose: Both hormone therapy (HT) and antiretroviral therapy (ART) can be lifesaving for transgender women (TW) living with HIV, but each has side effects and potential drug-drug interactions (DDI). We assessed how concerns about HT-ART interactions affect treatment adherence. Methods: This study used a cross-sectional survey of TW (n = 87) in Los Angeles, CA. Results: Fifty-four percent were living with HIV; 64% used HT. Only 49% of TW living with HIV discussed ART-HT DDI with their provider; 40% reported not taking ART (12%), HT (12%), or both (16%) as directed due to DDI concerns. Conclusion: Imperfect HT/ART use and limited provider communication suggests a need for improved HT-ART integration.
Type:
info:eu-repo/semantics/article
Rights:
info:eu-repo/semantics/restrictedAccess
Language:
eng
Description:
El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.
Keywords:
Antiretroviral therapy; Health disparities; HIV; Medication Adherence; Transgender
ISSN:
2325-8292; 2325-8306
Email:
Jordan.E.Lake@uth.tmc.edu

Full metadata record

DC FieldValue Language
dc.contributor.authorBraun, Hannan M.es
dc.contributor.authorCandelario, Juryes
dc.contributor.authorHanlon, Courtney L.es
dc.contributor.authorSegura, Eddy R.es
dc.contributor.authorClark, Jesse L.es
dc.contributor.authorCurrier, Judith S.es
dc.contributor.authorLake, Jordan E.es
dc.date.accessioned2017-10-30T14:13:10Z-
dc.date.available2017-10-30T14:13:10Z-
dc.date.issued2017-10-
dc.identifier.citationTransgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug–Drug Interaction Concerns 2017, 4 (5):371 LGBT Healthes
dc.identifier.issn2325-8292-
dc.identifier.issn2325-8306-
dc.identifier.doi10.1089/lgbt.2017.0057-
dc.identifier.urihttp://hdl.handle.net/10757/622329-
dc.descriptionEl texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.es_PE
dc.description.abstractPurpose: Both hormone therapy (HT) and antiretroviral therapy (ART) can be lifesaving for transgender women (TW) living with HIV, but each has side effects and potential drug-drug interactions (DDI). We assessed how concerns about HT-ART interactions affect treatment adherence. Methods: This study used a cross-sectional survey of TW (n = 87) in Los Angeles, CA. Results: Fifty-four percent were living with HIV; 64% used HT. Only 49% of TW living with HIV discussed ART-HT DDI with their provider; 40% reported not taking ART (12%), HT (12%), or both (16%) as directed due to DDI concerns. Conclusion: Imperfect HT/ART use and limited provider communication suggests a need for improved HT-ART integration.es
dc.formatapplication/pdfes
dc.language.isoenges
dc.publisherMary Ann Liebert Inc.es
dc.relation.urlhttp://online.liebertpub.com/doi/10.1089/lgbt.2017.0057es
dc.rightsinfo:eu-repo/semantics/restrictedAccesses
dc.subjectAntiretroviral therapyes
dc.subjectHealth disparitieses
dc.subjectHIVes
dc.subjectMedication Adherencees
dc.subjectTransgenderes
dc.titleTransgender Women Living with HIV Frequently Take Antiretroviral Therapy and/or Feminizing Hormone Therapy Differently Than Prescribed Due to Drug–Drug Interaction Concernses
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.journalLGBT Healthes
dc.contributor.institutionSchool of Medicine, University of California, San Francisco, San Francisco, California.-
dc.contributor.institutionAPAIT, Special Service for Groups, Los Angeles, California.-
dc.contributor.institutionGeisel School of Medicine, Dartmouth College, Hanover, New Hampshire.-
dc.contributor.institutionSouth American Program in HIV Prevention Research, Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, Los Angeles, California.-
dc.contributor.institutionSouth American Program in HIV Prevention Research, Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, Los Angeles, California.-
dc.contributor.institutionSouth American Program in HIV Prevention Research, Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, Los Angeles, California.-
dc.contributor.institutionSouth American Program in HIV Prevention Research, Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine, Los Angeles, California.-
dc.description.peerreviewRevisión por pareses_PE
dc.contributor.emailJordan.E.Lake@uth.tmc.edues_PE
All Items in UPC are protected by copyright, with all rights reserved, unless otherwise indicated.